Shares of Lantern Pharma (NASDAQ:LTRN) jumped 10% following the announcement that its cancer therapy LP-184 met all primary endpoints in a Phase 1a trial, showing a favorable safety profile and promising antitumor activity in patients with advanced solid tumors.
The AI-driven oncology company said the open-label, multicenter study evaluated LP-184 in 63 patients with advanced, relapsed, or refractory solid tumors, including glioblastoma multiforme (GBM). Clinical benefit was observed in 48% of evaluable patients receiving therapeutic doses, with durable responses in difficult-to-treat cancers.
LP-184 demonstrated a strong safety profile, with mostly Grade 1 or 2 adverse events such as manageable nausea and vomiting that resolved without significant intervention. The low incidence of Grade 3+ events highlights the drug’s tolerability, supporting potential use both as a monotherapy and in combination treatments.
“On behalf of our dedicated team, we extend our sincere gratitude to the patients, families, investigators, and clinical staff whose commitment drove the success of our Phase 1a LP-184 trial, establishing a robust safety profile with encouraging signals of activity at therapeutic doses,” said Panna Sharma, Chief Executive Officer of Lantern Pharma.
The company has established a recommended Phase 2 dose of 0.39 mg/kg and plans to advance multiple Phase 1b/2 trials. Upcoming studies will focus on triple-negative breast cancer in combination with the PARP inhibitor Olaparib, non-small cell lung cancer with specific mutations, and bladder cancer in patients with DNA damage repair genetic alterations.
Lantern highlighted biomarker data from the trial demonstrating LP-184’s potential in DDR-mutated cancers, including notable tumor reductions in patients with CHK2, ATM, and STK11/KEAP1 alterations. According to the company, the cancer indications targeted in future trials represent markets with over $6 billion in annual potential.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.